Deals channel feed – Endpoints News

Deals channel feed

Hearing-focused biotech grabs trio of programs from Otonomy's fire sale

3 years ago

AstraZeneca axes license agreement with Aridis, placing Europe-funded PhIII on hold

3 years ago

Evotec’s CNS deal with Bristol Myers gets $50M infusion and eight-year extension

3 years ago

Novartis rides with Bicycle for new pact on targeted radiotherapies

3 years ago

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders

3 years ago

AbbVie drops CytomX partnership, leaving PhII program in the air

3 years ago

Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends

3 years ago

Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality

3 years ago

Jounce nixes Redx offer as I/O biotech instead goes with Concentra Biosciences’ takeover bid

3 years ago

Venture investing without the GSK tie-up? Simeon George and the SR One team score a $600M fund to pave the way forward

3 years ago

NK cell therapy-focused biotech eyes SPAC deal

3 years ago

Moderna partners on non-viral gene therapy with Generation Bio after swinging gene editing deals

3 years ago

Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful

3 years ago

Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona, a fellow summer 2020 buyout option

3 years ago

Biohaven grabs TYK2/JAK1 drug for $20M to start, $950M on the line — to go after Parkinson's

3 years ago

In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

3 years ago

BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal

3 years ago

Gilead taps Nurix protein degrader option for $20M

3 years ago

Syneos Health inks deal with Microsoft to use AI technology

3 years ago

Daiichi and Zymeworks end antibody pact after seven years

3 years ago

Novartis and Biogen pull out of neuro drug partnerships with Sangamo

3 years ago

What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that

3 years ago

BeiGene decides not to license DKK1 drug, but keeps PD-1 combo trial in gastric cancer

3 years ago

Dr. Reddy’s divests $33M worth of dermatology brands in India

3 years ago

First page Previous page 38 39 404142 43 44 Next page Last page